Evaluating Immune Checkpoint Inhibition Response Biomarkers
Targeting the anti-tumor immune response has become a widely used strategy for the therapy of patients with advanced solid tumors, but not all patients respond, and immune-related side effects plus the high cost of these therapies increase the need for effective biomarkers to ensure that the immune checkpoint inhibitors are used in patients with the best chance of success. Clinicians need to be aware of the assays that are most appropriate to use based on the tumor type and the pitfalls of each testing technology.
Category
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Clinical Scenario #1: Applying Biomarkers in Risk Stratification of Localized Prostate Cancer
To provide optimal patient care, clinicians need to be well informed about the factors affecting the selection of the appropriate tests, the nuances of analyzing and interpreting complex test results in order to select the most appropriate treatment for their patients, and how to communicate with patients about the results.
Category
  • Prostate Cancer
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Clinical Scenario #2: Applying Biomarkers in Breast Cancer
To provide optimal patient care, clinicians need to be well informed about the factors affecting the selection of the appropriate tests, the nuances of analyzing and interpreting complex test results in order to select the most appropriate treatment for their patients, and how to communicate with patients about the results.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Clinical Scenario #3: Applying Biomarkers in Central Nervous System Cancers
To provide optimal patient care, clinicians need to be well informed about the factors affecting the selection of the appropriate tests, the nuances of analyzing and interpreting complex test results in order to select the most appropriate treatment for their patients, and how to communicate with patients about the results.
Category
  • Central Nervous System Cancers
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Clinical Scenario #4: Applying Biomarkers in Non-Small Cell Lung Cancer
To provide optimal patient care, clinicians need to be well informed about the factors affecting the selection of the appropriate tests, the nuances of analyzing and interpreting complex test results in order to select the most appropriate treatment for their patients, and how to communicate with patients about the results.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Clinical Scenario #5: Applying Biomarkers in Biliary Tract Cancers
To provide optimal patient care, clinicians need to be well informed about the factors affecting the selection of the appropriate tests, the nuances of analyzing and interpreting complex test results in order to select the most appropriate treatment for their patients, and how to communicate with patients about the results.
Category
  • Hepatobiliary Cancers
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
What Drives Reimbursement for Biomarker Testing?
As the policy and coverage landscape evolves, healthcare professionals can benefit from understanding the implications of coverage policies for appropriate biomarker testing for their patients.
Category
Format
  • Recorded Webcast
Credits
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
Archived Monthly Oncology Tumor Boards: Advances in Systemic Treatment of Metastatic Cutaneous Melanoma
The rapidly evolving treatment landscape for metastatic cutaneous melanoma is reflected in the new update of the NCCN Guidelines for Cutaneous Melanoma. Being familiar with the most current recommendations by the NCCN Panel will help clinicians in their multidisciplinary collaborations and to better support their patients.
Category
  • Melanoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Recorded Presentation from the NCCN Pharmacy Updates: Updates on Targeted Therapy for the Treatment of Thyroid Carcinoma
Pharmacists should be aware of the new data and recommendations for targeted therapies, and how they relate to improvements in clinical efficacy and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies.
Category
  • Thyroid Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Advances in Hepatocellular and Biliary Tract Cancers Impacting Patient Outcomes
The goal of this program is to improve the knowledge and competence of learners to individualize the therapeutic management of patients with hepatobiliary cancers.
Category
  • Hepatobiliary Cancers
  • Hepatocellular Carcinoma
Format
  • Recorded Webcast
Credits
  • 1.75 AAPA Category 1 CME credit
  • 1.75 ACPE contact hours
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC contact hours
  • 1.75 Participation

Pages